ZANVASTRO Wins First-in-Disease Crown, But Pivotal Evidence Sits at the Margin

Ionis' ZANVASTRO Gains FDA Approval for Alexander Disease

Ionis Pharmaceuticals announced FDA approval for ZANVASTRO (zilganersen) on September 3, 2026, as the first and only disease-modifying treatment for Alexander disease (AxD) in pediatric and adult patients. AxD is an ultra-rare, progressive, and often fatal neurological disorder. ZANVASTRO is an RNA-targeted medicine that reduces glial fibrillary acidic protein (GFAP) production, administered quarterly via intrathecal injection. The approval was supported by a pivotal study showing statistically significant stabilization of gait speed in patients ≥ 5 years old (p=0.041) and improved gross motor function in younger patients. Ionis also received a Rare Pediatric Disease Priority Review Voucher.

• The FDA approval of ZANVASTRO was based on positive results from a pivotal Phase 1-3 study (NCT04849741) involving 54 participants. The study met its primary endpoint in patients ≥ 5 years of age, demonstrating a statistically significant and clinically meaningful stabilization of gait speed (least square mean difference 33.3%, p=0.041) as measured by the 10-Meter Walk Test at Week 61. Additionally, patients aged 2 to 4 years showed improvement in gross motor function via the Gross Motor Function Measure-88.
• ZANVASTRO (zilganersen) is an innovative RNA-targeted medicine designed to address the root cause of Alexander disease by reducing the overproduction and toxic accumulation of glial fibrillary acidic protein (GFAP) in astrocytes. This mechanism aims to prevent damage to neurons and myelin. The drug is administered quarterly as a 50 mg intrathecal (IT) injection, offering a targeted delivery approach for this neurological disorder.
• In addition to the FDA approval, Ionis Pharmaceuticals was awarded a Rare Pediatric Disease Priority Review Voucher (PRV), incentivizing therapies for serious rare diseases. Ionis has also established a license agreement with Recordati, granting them exclusive rights to develop and commercialize zilganersen in all countries outside the U.S., with regulatory submissions in Europe and Japan anticipated in 2027. This outlines a clear global commercialization strategy.

The Burden of Alexander Disease and Current Treatment Gaps

Alexander disease (AxD) remains without a curative treatment, with current approaches limited to symptomatic management. The rarity and severity of the disease, combined with an incompletely understood pathophysiology, have historically constrained therapeutic development — though emerging modalities are beginning to shift this landscape.

• No established disease-modifying therapy exists. AxD is classified among the leukodystrophies for which no approved treatment is available. Management remains symptom-focused, and the prognosis for Type I (infantile) AxD is poor, with patients experiencing paroxysmal neurodegeneration, refractory epilepsy, and encephalopathy.

• Seizure control is frequently inadequate with standard anti-seizure medications. In documented cases, seizures have failed to respond to valproate, clonazepam, and phenobarbital. Only the addition of perampanel, a postsynaptic AMPA receptor antagonist, achieved seizure freedom — and only for a limited observation period of more than 3 months in one reported case.

• Symptomatic treatments are largely anecdotal and case-based. Mild symptomatic improvement with ceftriaxone was reported in one adult AxD case, and amoxicillin (80 mg/kg/day) produced striking improvement in irritability within 48 hours in one infantile case — but these findings have not been validated in controlled trials.

• Gene therapy and antisense oligonucleotide (ASO) trials are ongoing but not yet established. Alexander disease is among only eight leukodystrophies with existing gene therapy clinical trials, and ASO-based approaches remain in development. The ultrarare nature of most leukodystrophies, limited natural history data, high treatment costs, and barriers to accessibility are cited as persistent challenges across this disease class.

• Pathophysiological mechanisms remain incompletely characterized. The mechanisms of Rosenthal fiber formation are unclear, and no definitive phenotype-genotype correlation has been established for most GFAP mutations, complicating the design of targeted therapies. Both the quality and quantity of GFAP are recognized as important, but the precise downstream pathology — including the role of glutamatergic excitotoxicity — continues to be investigated.

ZANVASTRO's Pivotal Study: Efficacy and Safety Highlights

Two recent studies offer meaningful insights into Alexander disease (AxD) interventions. The study "Antisense therapy in a rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment" (2022) evaluated a Gfap-targeted antisense oligonucleotide (ASO) in a rat model of AxD. This model exhibited hallmark pathology including GFAP aggregation in the form of Rosenthal fibers, widespread astrogliosis, and white matter deficits, with animals developing severe motor deficits as they matured and approximately 14% dying of unknown cause between 6 and 12 weeks of age. A single treatment with the Gfap-targeted ASO provided long-lasting suppression, reversed GFAP pathology, and — depending on age of treatment — prevented or mitigated white matter deficits and motor impairment, demonstrating that ASO therapy has the potential to not only prevent but also reverse many aspects of disease.

The study "Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease" (2024) did not evaluate a therapeutic intervention directly but addressed a critical gap in AxD disease monitoring by characterizing plasma biomarkers. GFAP was found to be elevated in plasma across all age groups afflicted by AxD, including those with adult onset. Neurofilament light protein (NfL) and phosphorylated tau (p-tau) were also elevated, but to a much lesser extent than GFAP. In contrast, levels of Aβ40 and Aβ42 were not altered in AxD. The study highlighted that because ASO therapy — the treatment furthest in development — targets GFAP directly, GFAP levels would be expected to decline independent of disease status, underscoring the critical need for complementary biomarkers such as NfL and p-tau to monitor disease progression and treatment response.

The broader review "Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials" (2024) confirmed that Alexander disease is among the eight leukodystrophies with existing gene therapy clinical trials, with intrathecal antisense oligonucleotide approaches among the modalities under investigation. The review noted that gene therapy, while promising, requires systematic monitoring to account for the precarious disease biology and adverse events associated with new technology, specifically citing genotoxicity and immunotoxicity as key safety considerations across modalities including ex vivo lentiviral gene delivery, in vivo AAV-mediated gene delivery, and intrathecal ASO approaches.

Understanding ZANVASTRO's Safety and Tolerability Profile

The available literature on Alexander disease (AxD) addresses therapeutic strategies, biomarkers, and disease mechanisms, but does not report specific adverse event data or safety signals from clinical trials. The knowledge base does not have sufficient information to answer this question.

A New Era for Alexander Disease Treatment

The recent FDA approval of ZANVASTRO for Alexander disease (AxD) marks a significant milestone, ushering in a new era for patients grappling with this devastating neurological disorder. For decades, management of AxD has been limited to supportive care, addressing symptoms without tackling the underlying pathology. ZANVASTRO, as the first and only disease-modifying treatment, fundamentally shifts this paradigm.

This RNA-targeted medicine directly addresses the root cause of AxD by reducing the production of glial fibrillary acidic protein (GFAP), which accumulates abnormally in astrocytes and leads to the characteristic Rosenthal fibers and astrocyte dysfunction seen in the disease. The clinical evidence supporting this approval, demonstrating stabilization of gait speed and improved gross motor function, offers tangible hope for patients across the broad spectrum of AxD, from pediatric to adult onset.

However, the path forward is not without its complexities. Alexander disease is notoriously heterogeneous, with a wide range of clinical presentations, disease progression rates, and over 100 reported GFAP mutations. While genotype-phenotype correlations are emerging for some variants, the variability means that individual patient responses to ZANVASTRO may differ. Furthermore, the invasive nature of quarterly intrathecal injections, while necessary for central nervous system delivery, presents logistical challenges for patients and healthcare systems, particularly for a chronic condition in an ultra-rare population. The long-term impact on the most severe, rapidly progressing forms, such as neonatal AxD, will also be a critical area for continued observation.

Beyond AxD, this approval validates the broader potential of RNA-targeted therapies for neurological conditions, particularly those involving protein aggregation or specific genetic mutations. The success of ZANVASTRO could pave the way for similar approaches in other rare leukodystrophies and neurodegenerative diseases, leveraging the precision and specificity of this therapeutic modality. The accompanying Rare Pediatric Disease Priority Review Voucher further underscores the value of addressing these high unmet needs and incentivizes continued innovation in the rare disease space.